The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.
 
Biagio Ricciuti
No Relationships to Disclose
 
Michael L. Cheng
No Relationships to Disclose
 
Gonzalo Recondo
No Relationships to Disclose
 
Mizuki Nishino
Honoraria - Bayer Yakuhin; Roche Pharma AG
Consulting or Advisory Role - Daiichi Sankyo; Toshiba; WorldCare Clinical, LLC
Research Funding - AstraZeneca (Inst); Merck (Inst); Toshiba (Inst)
 
Renato Umeton
No Relationships to Disclose
 
Lynette M. Sholl
Consulting or Advisory Role - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
Other Relationship - Gfk; Research to Practice
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb